Yan-Ling Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan-Ling Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Lin-Yan Huang
School of Medical Technology, Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Tongshan Road 209, Xuzhou 221004, China
2 shared publications - Suhua Qi
School of Medical Technology, Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Xuzhou, People’s Republic of China
2 shared publications - Wan Wang
Xuzhou Key Laboratory of Laboratory Diagnostics, School of Medical Technology, Xuzhou Medical University, Xuzhou, China
2 shared publications - Bin Wang
Pharmacology College, Xuzhou Medical University, Xuzhou 221004, China; Department of Laboratory Medicine, The Affiliated Hospital of Xuzhou Medical University, No.99 Huaihai West Road, Xuzhou, 221000, China
1 shared publication - Hai-Di Fan
College of Pharmacology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
1 shared publication - Heng Cai
College of Pharmacology, Xuzhou Medical University, Xuzhou, Jiangsu Province, China
1 shared publication
Latest Publications
- 22 July 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Disintegration of Cav-1/β-catenin complex attenuates neuronal death after ischemia–reperfusion injury by promoting β-catenin nuclear translocation
Background The roles of Caveolin-1 (Cav-1) and the Wnt/β-catenin signaling pathways in cerebral ischemia–reperfusion (I/R) injury are well established. The translocation of β-catenin into the nucleus is critical for regulating neuronal apoptosis, repair, and neurogenesis within the ischemic brain. It has been reported that the scaffold domain of Caveolin-1 (Cav-1) (residues 95–98) interacts with β-catenin (residues 330–337). However, the specific contribution of the Cav-1/β-catenin complex to I/R injury remains unknown. Methods and results To investigate the mechanism underlying the involvement of the Cav-1/β-catenin complex in the subcellular translocation of β-catenin and its subsequent effects on cerebral I/R injury, we treated ischemic brains with ASON (Cav-1 antisense oligodeoxynucleotides) or FTVT (a competitive peptide antagonist of the Cav-1 and β-catenin interaction). Our study demonstrated that the binding of Cav-1 to β-catenin following I/R injury prevented the nuclear accumulation of β-catenin. Treatment with ASON or FTVT after I/R injury significantly increased the levels of nuclear β-catenin. Furthermore, ASON reduced the phosphorylation of β-catenin at Ser33, Ser37, and Thr41, which contributes to its proteasomal degradation, while FTVT increased phosphorylation at Tyr333, which is associated with its nuclear translocation. Conclusions The above results indicate that the formation of the Cav-1/β-catenin complex anchors β-catenin in the cytoplasm following I/R injury. Additionally, both ASON and FTVT treatments attenuated neuronal death in ischemic brains. Our study suggests that targeting the interaction between Cav-1 and β-catenin serve as a novel therapeutic strategy to protect against neuronal damage during cerebral injury.
- 22 July 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Disintegration of Cav-1/β-catenin complex attenuates neuronal death after ischemia–reperfusion injury by promoting β-catenin nuclear translocation
Background The roles of Caveolin-1 (Cav-1) and the Wnt/β-catenin signaling pathways in cerebral ischemia–reperfusion (I/R) injury are well established. The translocation of β-catenin into the nucleus is critical for regulating neuronal apoptosis, repair, and neurogenesis within the ischemic brain. It has been reported that the scaffold domain of Caveolin-1 (Cav-1) (residues 95–98) interacts with β-catenin (residues 330–337). However, the specific contribution of the Cav-1/β-catenin complex to I/R injury remains unknown. Methods and results To investigate the mechanism underlying the involvement of the Cav-1/β-catenin complex in the subcellular translocation of β-catenin and its subsequent effects on cerebral I/R injury, we treated ischemic brains with ASON (Cav-1 antisense oligodeoxynucleotides) or FTVT (a competitive peptide antagonist of the Cav-1 and β-catenin interaction). Our study demonstrated that the binding of Cav-1 to β-catenin following I/R injury prevented the nuclear accumulation of β-catenin. Treatment with ASON or FTVT after I/R injury significantly increased the levels of nuclear β-catenin. Furthermore, ASON reduced the phosphorylation of β-catenin at Ser33, Ser37, and Thr41, which contributes to its proteasomal degradation, while FTVT increased phosphorylation at Tyr333, which is associated with its nuclear translocation. Conclusions The above results indicate that the formation of the Cav-1/β-catenin complex anchors β-catenin in the cytoplasm following I/R injury. Additionally, both ASON and FTVT treatments attenuated neuronal death in ischemic brains. Our study suggests that targeting the interaction between Cav-1 and β-catenin serve as a novel therapeutic strategy to protect against neuronal damage during cerebral injury.
- Open Access
- 1 January 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 18 (5) , 1040-1045
Ischemic accumulation of succinate induces Cdc42 succinylation and inhibits neural stem cell proliferation after cerebral ischemia/reperfusion
JOURNAL/nrgr/04.03/01300535-202305000-00020/inline-graphic1/v/2022-10-11T005158Z/r/image-tiff
- 1 January 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 18 (5) , 1040-1045
Open AccessIschemic accumulation of succinate induces Cdc42 succinylation and inhibits neural stem cell proliferation after cerebral ischemia/reperfusion
JOURNAL/nrgr/04.03/01300535-202305000-00020/inline-graphic1/v/2022-10-11T005158Z/r/image-tiff